Case ReportTherapeutic Drug Monitoring-Guided Crushed Sofosbuvir-Velpatasvir Treatment A Case StudyLalanne, Sébastien MSc*,†; Jézéquel, Caroline MD‡; Tron, Camille PharmD, PhD*,†; Verdier, Marie-Clémence PharmD, PhD*,†; Mercerolle, Marion PharmD§; Pronier, Charlotte PharmD¶; Guyader, Dominique MD, PhD†,‡; Lemaitre, Florian PharmD, PhD*,†Author Information *Department of Biological and Clinical Pharmacology, Faculty of Medicine, Rennes University Hospital; †Inserm, CIC-P 1414 Clinical Investigation Center; ‡Liver Disease Unit, Rennes University Hospital; Departments of §Pharmacy; and ¶Virology, Rennes University Hospital, Rennes, France. Correspondence: Sébastien Lalanne, Department of Biological and Clinical Pharmacology, Rennes University Hospital, 35000 Rennes, France (e-mail: email@example.com). The authors declare no conflict of interest. Received September 22, 2019 Accepted October 28, 2019 Therapeutic Drug Monitoring: April 2020 - Volume 42 - Issue 2 - p 163-164 doi: 10.1097/FTD.0000000000000718 Buy Metrics Abstract In this study, the authors report the case of a patient diagnosed with hepatitis C virus who was treated with sofosbuvir–velpatasvir (400/100 mg). As the patient was unable to swallow whole tablets, therapeutic drug monitoring was performed to evaluate the effect of crushing sofosbuvir–velpatasvir tablets on drug absorption and global exposure. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.